𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Triptolide modulates T-cell inflammatory responses and ameliorates experimental autoimmune encephalomyelitis

✍ Scribed by Ying Wang; Yunhua Mei; Dechun Feng; Lingyun Xu


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
322 KB
Volume
86
Category
Article
ISSN
0360-4012

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Triptolide (TPT), a diterpenoid triepoxide, is the major component isolated from the Chinese herb Tripterygium wilfordii Hook. f. Previous studies have shown that TPT has immunosuppressive properties and is effective in prolonging graft survival and suppressing autoimmune responses. The aim of this study was to investigate theprotective effect of TPT in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. Treatment of C57BL/6 mice with TPT from the date of EAE induction significantly delayed EAE onset and suppressed disease severity, accompanied with reduced inflammation and demyelination in the central nervous system. TPT treatment lead to a significant inhibition of the mRNA expression of both Th1/Th~IL‐17~ and Th2 cytokines in spleen mononuclear cells (MNC) as well as in spinal cord tissues. In addition, the expression of Forkhead box p3 (Foxp3) was up‐regulated in spleen MNC after TPT treatment. Furthermore, we detected apparent inhibition of nuclear factor–kappa B (NF‐κB)‐DNA binding activity, increased expression of the inhibitor of nuclear factor–kappa Bα (IκBα) and decreased expression of pIκBα in spleen MNC in TPT‐treated EAE mice. Taken together, these findings indicate that TPT has profound immunoregulatory functions and potential protective values for the treatment of autoimmune inflammatory disorders. © 2008 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


FTY720 ameliorates MOG-induced experimen
✍ Dimitrios Papadopoulos; Jon Rundle; Ryan Patel; Ian Marshall; Jennifer Stretton; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 593 KB

## Abstract FTY720, an oral sphingosine 1‐phosphate (S1P) receptor modulator, has shown efficacy in phase II trials in patients with relapsing‐remitting multiple sclerosis (MS). Although this molecule is thought to immunosuppress by inhibiting lymphocyte egress from the lymph nodes, the full spectr

Down-modulation of programmed death 1 al
✍ Chunhe Wang; Yuexin Li; Thomas M. Proctor; Arthur A. Vandenbark; Halina Offner 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 585 KB

## Abstract The regulatory role of programmed death 1 (PD‐1) was investigated in the development of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. Typical EAE could be induced by immunization without pertussis toxin (PTX) in PD‐1‐null but not in wild‐type (W

Treatment with selective estrogen recept
✍ Bruce F. Bebo Jr.; Babak Dehghani; Scott Foster; Astrid Kurniawan; Francisco J. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 605 KB

## Abstract Steroidal estrogens can regulate inflammatory immune responses and may be involved in the suppression of multiple sclerosis (MS) during pregnancy. However, the risks and side effects associated with steroidal estrogens may limit their usefulness for long‐term MS therapy. Selective estro